Results 171 to 180 of about 221,455 (333)
Updated COVID‐19 Vaccines and Health Outcomes in Patients With Autoimmune Rheumatic Conditions
Arthritis &Rheumatology, EarlyView.Objective We aimed to assess the association between COVID‐19 vaccination status and COVID‐19‐related hospital admissions, need for mechanical ventilation or extracorporeal membrane oxygenation (ECMO), and death in people with autoimmune rheumatic conditions. Methods We conducted a retrospective cohort study using National Clinical Cohort Collaborative
Lesley E. Jackson +127 more
wiley +1 more source
CAQ Corner: Immune‐mediated complications
, 2022 Liver Transplantation, EarlyView.
Mary Thomson, John R. Lake
wiley +1 more source
Schematic representation of present method for measuring rituximab in plasma.
, 2017 Isolation of rituximab from plasma was conducted by anti-rituximab antibodies covalently bound to magnetic beads. Isolated rituximab was digested by papain, and then the structures of rituximab were analyzed by LC/TOF-MS.
Shunsaku Nakagawa (430323) +9 more
core +1 more source
Abatacept Reduces CD319+ (SLAMF7) Cytotoxic T Cells and Cytokine Production in Systemic Sclerosis
Arthritis &Rheumatology, EarlyView.Objective Systemic sclerosis (SSc) is characterized by immune dysregulation and fibrosis. We investigated whether abatacept modulates CD319/SLAMF7‐expressing cytotoxic T cells implicated in diffuse cutaneous SSc. Methods In this ancillary ASSET trial analysis, peripheral blood mononuclear cells from 67 participants were analyzed at baseline and months ...
Mikel Gurrea‐Rubio +15 more
wiley +1 more source
Outcomes of primary gastrointestinal diffuse large B cell lymphoma in the rituximab era
Discover OncologyBackground Primary gastrointestinal diffuse large B-cell lymphoma (PGI-DLBCL) constitutes 30%-40% of primary extranodal lymphomas. While rituximab has significantly improved survival in nodal DLBCL, its impact on the prognosis of PGI-DLBCL remains ...
Luyao Zhang +6 more
doaj +1 more source
Cancer in Systemic Sclerosis: Clinical Associations and Prognostic Impact From the EUSTAR Registry
Arthritis &Rheumatology, EarlyView.Objective Cancer represents a major cause of death in systemic sclerosis (SSc). Established risk factors are limited to specific subsets, particularly early diffuse anti‐RNA polymerase III (POLR3)–positive disease, needing further exploration. Methods We performed a nested case‐control study within the European Scleroderma Trials and Research group ...
Antonio Tonutti +52 more
wiley +1 more source
Arthritis &Rheumatology, EarlyView.Objective Information is limited on the natural history and current treatment patterns in macrophage activation syndrome (MAS), a life‐threatening hyperinflammatory syndrome complicating Still's disease (systemic juvenile idiopathic arthritis [sJIA] and adult‐onset Still's disease [AOSD]).
Alexei Grom +21 more
wiley +1 more source
Therapeutic Advances in OphthalmologyRituximab, an anti-CD-20 monoclonal antibody, has garnered increasing interest as a therapeutic option in orbital inflammatory disease (OID). We report our institutional experience with intralesional rituximab injections in two cases of orbital ...
Terence Ang +2 more
doaj +1 more source
Effect of rituximab treatment on PCP risk.
, 2015 M-H pooled risk ratio = 3.65, fixed effect model method. R: rituximab. Rituximab increased the risk for PCP in lymphoma patients significantly.
Xiaojing Wang (147040) +3 more
core +1 more source